← All trials
NCT00637806
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2006
- Primary completion
- Sep 1, 2006
- Completion date
- Sep 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 4
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Par PharmaceuticalsLead sponsor
- Par PharmaceuticalsStudy chair
- Summit Oncology Associates, Inc.Overall official - principal investigator
- Pacific Cancer Medical Center Inc.Overall official - principal investigator
- Wake Forest UniversityOverall official - principal investigator
- Forum HealthOverall official - principal investigator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.